Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager.

ABSTRACT:

Background

The glycosylphosphatidylinositol-anchored cell surface protein mesothelin (MSLN) shows elevated expression in many malignancies and is an established clinical-stage target for antibody-directed therapeutic strategies. Of these, the harnessing of autologous patient T cells via engineered anti-MSLN chimeric antigen receptors (CAR-T) is an approach garnering considerable interest. Although generally shown to target tumor MSLN safely, CAR-T trials have failed to deliver the impressive curative or response metrics achieved for hematological malignancies using the same technology. A need exists, therefore, for improved anti-MSLN molecules and/or more optimal ways to leverage immune effector cells.

Methods

We performed ELISA, label-free kinetic binding assays, FACS, West

SUBMITTER: Kosti P 

PROVIDER: S-EPMC11907088 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature